Humana Inc (HUM) Expected to Post Quarterly Sales of $13.02 Billion
Wall Street brokerages expect Humana Inc (NYSE:HUM) to post sales of $13.02 billion for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Humana’s earnings. The lowest sales estimate is $12.89 billion and the highest is $13.12 billion. Humana reported sales of $13.46 billion during the same quarter last year, which indicates a negative year-over-year growth rate of 3.3%. The firm is expected to report its next quarterly earnings results before the market opens on Wednesday, February 7th.
According to Zacks, analysts expect that Humana will report full-year sales of $13.02 billion for the current year, with estimates ranging from $52.44 billion to $54.10 billion. For the next year, analysts anticipate that the company will post sales of $56.36 billion per share, with estimates ranging from $54.59 billion to $57.55 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Humana.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $13.41 billion. During the same quarter in the prior year, the firm posted $3.18 earnings per share. Humana’s revenue for the quarter was down 3.0% compared to the same quarter last year.
Shares of Humana (NYSE HUM) traded up $2.15 during midday trading on Tuesday, reaching $270.17. The company’s stock had a trading volume of 1,690,900 shares, compared to its average volume of 1,204,290. Humana has a 12-month low of $186.25 and a 12-month high of $271.99. The firm has a market capitalization of $38,440.00, a PE ratio of 21.27, a P/E/G ratio of 1.70 and a beta of 0.88. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date is Thursday, December 28th. Humana’s payout ratio is 12.60%.
Humana announced that its Board of Directors has authorized a share repurchase program on Thursday, December 14th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the insurance provider to purchase shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its shares are undervalued.
In related news, SVP Jody L. Bilney sold 7,054 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $247.89, for a total value of $1,748,616.06. Following the sale, the senior vice president now directly owns 11,704 shares in the company, valued at approximately $2,901,304.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Brian P. Leclaire sold 1,679 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total value of $412,983.63. Following the completion of the sale, the senior vice president now owns 9,888 shares in the company, valued at $2,432,151.36. The disclosure for this sale can be found here. Insiders have sold a total of 10,115 shares of company stock worth $2,501,627 over the last quarter. Insiders own 0.80% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Koch Industries Inc. acquired a new stake in Humana in the 2nd quarter valued at approximately $404,000. Adviser Investments LLC bought a new stake in shares of Humana during the 3rd quarter worth $635,000. Wells Fargo & Company MN boosted its stake in shares of Humana by 10.0% during the 3rd quarter. Wells Fargo & Company MN now owns 1,653,318 shares of the insurance provider’s stock worth $402,799,000 after acquiring an additional 150,173 shares in the last quarter. Commonwealth Bank of Australia boosted its stake in shares of Humana by 3.9% during the 3rd quarter. Commonwealth Bank of Australia now owns 21,112 shares of the insurance provider’s stock worth $5,138,000 after acquiring an additional 796 shares in the last quarter. Finally, Icon Advisers Inc. Co. boosted its stake in shares of Humana by 22.7% during the 3rd quarter. Icon Advisers Inc. Co. now owns 5,400 shares of the insurance provider’s stock worth $1,316,000 after acquiring an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Humana Inc (HUM) Expected to Post Quarterly Sales of $13.02 Billion” was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/16/humana-inc-hum-expected-to-post-quarterly-sales-of-13-02-billion.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.